ストックスクリーナーアプリを入手
6.6837
2.27%
-0.1563
前日終値:
$6.84
開ける：
$6.82
24時間の取引高:
589.53K
Relative Volume:
0.14
時価総額：
$1.66B
収益：
$557.51M
当期純損益:
$-35.71M
株価収益率:
-37.13
EPS:
-0.18
ネットキャッシュフロー:
$15.50M
1週間 パフォーマンス:
+7.13%
1か月 パフォーマンス:
-5.71%
6か月 パフォーマンス:
-19.94%
1年 パフォーマンス:
-23.86%
1日の値動き範囲:
$6.61
$6.86
1週間の範囲:
$6.26
$6.905
52週間の値動き範囲:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
名前
Biocryst Pharmaceuticals Inc
セクター
電話
919-859-1302
住所
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs ZTS, TAK, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
6.69 | 1.70B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
131.26 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.33 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
HLN
Haleon Plc Adr
|
11.18 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.94 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
474.38 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-15 | 再開されました | TD Cowen | Buy |
| 2025-10-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 開始されました | Wedbush | Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-09-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-13 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-02-22 | アップグレード | Needham | Hold → Buy |
| 2022-11-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2022-08-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-04-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-12-10 | 開始されました | Oppenheimer | Outperform |
| 2021-08-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 開始されました | Cowen | Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Overweight |
| 2020-06-17 | 開始されました | BTIG Research | Neutral |
| 2020-05-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-11-15 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 再開されました | Piper Jaffray | Overweight |
| 2018-08-08 | 再開されました | JP Morgan | Overweight |
| 2018-07-17 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 開始されました | Seaport Global Securities | Neutral |
| 2018-01-02 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 開始されました | Barclays | Equal Weight |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-09-06 | アップグレード | Jefferies | Hold → Buy |
| 2017-02-16 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-08-12 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 繰り返されました | FBR Capital | Outperform |
| 2016-02-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2016-02-09 | ダウングレード | Needham | Buy → Hold |
すべてを表示
Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - The Manila Times
BioCryst Pharmaceuticals to Present Nine Abstracts on Hereditary Angioedema at 2026 AAAAI Annual Meeting - Quiver Quantitative
Shots every 3–6 months suppress HAE attacks in BioCryst trial data - Stock Titan
BioCryst to Present New HAE Data from ORLADEYO® - GlobeNewswire
What catalysts could drive BioCryst Pharmaceuticals Inc. stock higherMarket Performance Summary & Low Risk Profit Maximizing Plans - mfd.ru
Why BioCryst Pharmaceuticals Inc. stock is a must watch in 2025Earnings Miss & Weekly High Potential Stock Alerts - mfd.ru
BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap - Yahoo Finance
Jim Cramer on BioCryst Pharmaceuticals: "Just Stay Away From That" - Finviz
BioCryst Uses Equity Grants To Support Rare Disease Pipeline And Talent - Sahm
Jim Cramer on BioCryst Pharmaceuticals: “Just Stay Away From That” - Insider Monkey
(BCRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Jim Cramer Commented on These 14 Stocks - Insider Monkey
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - The Globe and Mail
ADARx Pharmaceuticals Appoints Donald Fong as CMO - Contract Pharma
BioCryst (BCRX) Grants Stock Options and RSUs to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | Nation/World | bdtonline.com - Bluefield Daily Telegraph
Will BioCryst's ORLADEYO Hit The $1 Billion Sales Mark? - RTTNews
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a Potential 226.80% Upside - DirectorsTalk Interviews
Biocryst expands HAE treatment portfolio with Astria acquisition - Angioedema News
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Steris (STE), Arcellx Inc (ACLX) and BioCryst (BCRX) - The Globe and Mail
BioCryst Pharmaceuticals Is Quietly Exploding – Is BCRX the Next Sleeper Biotech Rocket or a Total - AD HOC NEWS
BCRX: Analyst Maintains Rating but Lowers Price Target to $13 | - GuruFocus
Royal Bank Of Canada Lowers BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00 - MarketBeat
RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Keeps Outperform Rating - marketscreener.com
Is BioCryst Pharmaceuticals Inc. backed by strong institutional buyingRate Hike & AI Powered Buy/Sell Recommendations - Mfd.ru
Does Blackstone’s US$400 Million Deal and Astria Hires Change The Bull Case For BioCryst (BCRX)? - Sahm
Is BioCryst Pharmaceuticals Inc.’s growth already priced inJuly 2025 Final Week & AI Optimized Trade Strategies - mfd.ru
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A 198% Potential Upside for Investors - DirectorsTalk Interviews
(BCRX) Risk Channels and Responsive Allocation - Stock Traders Daily
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Pressure And Rare Disease Pipeline Focus - Yahoo Finance
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema - Sahm
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Mixed Recent Share Price Performance - Sahm
Astria Therapeutics Completes Merger and Goes Private - TipRanks
BioCryst Closes Blackstone Loan and Astria Acquisition - TipRanks
BioCryst Pharmaceuticals Signs Loan Agreement With Blackstone and Lenders - TradingView
Astria Therapeutics Signs Loan Agreement Joinder With BioCryst Pharmaceuticals - TradingView
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 5.3%Still a Buy? - MarketBeat
BioCryst Completes Acquisition of Astria Therapeutics (ATXS) - GuruFocus
BioCryst completes $700 million acquisition of Astria Therapeutics - Investing.com
BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics to Enhance HAE Portfolio - Quiver Quantitative
Hereditary Angioedema Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
BioCryst Pharmaceuticals, Inc. announced that it expects to receive $400 million in funding - marketscreener.com
BioCryst: The $700 Million Pivot From Oral Convenience To Injectable - Seeking Alpha
Clearside Biomedical Shares Surge Amid Bankruptcy Proceedings - AD HOC NEWS
Astria stockholders approve acquisition by BioCryst - Investing.com Australia
Astria stockholders approve acquisition by BioCryst By Investing.com - Investing.com South Africa
Astria Stockholders Vote to Approve Acquisition by BioCryst - citybiz
Astria stockholders vote to approve acquisition by BioCryst - marketscreener.com
Astria Therapeutics (ATXS) Stockholders Approve BioCryst Merger - GuruFocus
Biocryst Pharmaceuticals Inc (BCRX) 財務データ
収益
当期純利益
現金流量
EPS
0.46%
8.35%
大文字化:
|
ボリューム (24 時間):